Trial Profile
A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2020
Price :
$35
*
At a glance
- Drugs Elomotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Ipsen
- 19 Sep 2011 New trial record